➡️ Check our our latest paper
@LeukemiaJnl
on HyperCVAD+Nel+PegAsp w/wo VEN frontline Rx in adult pts with T-ALL/LBL
✅️mFU of 5yrs= med PFS and OS not reached (5yr rates: 64% & 66%)
✅️ VEN cohorts trend to fare better vs original cohorts: 2yr PFS: 88% vs 65%; OS 88% vs 74%
🙏🏼 I am happy to share that I have joined as Asst Prof in the Dept of Leukemia at MD Anderson Cancer Center, Houston. Years of education, training & blessings from well wishers have culminated into a surreal moment of joy. Hope to strive for the best for our patients & science 🙏🏼
DM in Clinical Haematology (AIIMS ND) it is! Thanks to my wife, family, and friends for supporting me throughout and my mentors for believing in me. Moving on to Leukemia fellowship at MDACC Houston
@MDAndersonNews
What an incredible fellow's graduation night with our esteemed faculty and mentors 🥂! I am blessed & grateful to be a part of this wonderful dept for the last yr. Humbled to receive the Research fellow of the year award 🙏🏼.
@DrHKantarjian
@TapKadia
@garciamanero
@MDAndersonNews
Words fail to express my sincere gratitude to the amazing Dept of Leukemia
@MDAndersonNews
&
@DrHKantarjian
for giving me this opportunity. I have met some of the nicest & most inspiring people here. 🙏🏼 to God, my parents & family, & my wife
@AnweshaRayS
for supporting me always.
Very happy to have reviewed with Prof
@Kadia
how to choose the right FLT3 inhibitor in patients with AML.
When options increase the right choice can get tougher!
@SpringerNature
➡️ Check out our latest paper reviewing the treatment of CML in 2023 in
@BloodCancerJnl
: we discuss the latest concepts in the field focussing on the ideal option for the patient👨🏻⚕️
Honored to have authored this paper under Prof
@DrHKantarjian
's mentorship.
@MDAndersonNews
#leusm
A profoundly treasured moment at
#ASH22
.
Proud feeling for any
@OffCMCVellore
alumnus to share the frame with a legend of the field Prof
@VincentRK
, who knowingly and unknowingly has inspired many across the 🌎 and 🇮🇳 to take up hematology as a career and passion.
Finishing the wonderful and invigorating month-long inpatient rotation with the awesome
@Daver_Leukemia
. Learnt a lot of leukemia and even beyond!
#leusm
@MDAndersonNews
✅ A small effort highlighting the challenges in the care of pts with AML in LMICs
@TheLancetHaem
: many efforts are being led by Govt & Pvt groups in India to reduce the gaps in AML care. The benefits of leuk research & improving outcomes should become a more global phenomenon 🌏
👨🏻⚕️Looking forward to share our long term follow up data of CRLF2 rearranged Ph-like ALL
@ASCO
2022, under the mentorship of
@NitinJainMD
.
Humbled to have received the ASCO Conquer Cancer Merit Award
@ConquerCancerFd
2022 🇺🇲🌍🇮🇳
Missing
#ASH23
but Ending Leukemia! 👨🏻⚕️ December Leukemia inpatient service at
@MDAndersonNews
.
The opportunity to help our patients, makes everyday a blessing! ☀️
✈ Off to Chicago for
#ASCO2022
. Proud to be a part of Leukemia
@MDAndersonNews
. Thanks to
@NitinJainMD
for the opportunity. Will be presenting our long term data of CRLF2 rearranged B-ALL.
#leusm
First time to ASCO. Wonderful feeling!
🚅 🚄The excitement 😃 of my first ride in the wonderful Vande Bharat express from Howrah to Puri today can only be matched by my first aeroplane ride as a kid in 2003! Way to go!
@RailMinIndia
@PMOIndia
@AshwiniVaishnaw
➡️ Happy to present our data on the outcomes of older patients with AML who underwent SCT in CR1 after Clad-LDAC-Ven alt with HMA-Ven regimen
@ASCO
(and compared with other regimens). Thanks to
@TapKadia
@DrHKantarjian
and to
@ConquerCancerFd
for the Merit Award (Abstract 7047).
An outstanding and comprehensive review by
@jayastuMD
out now in
@LeukemiaJnl
on the pathogenesis and management of accelerated and blast phase
#CML
. I honestly think he has written the most definitive review on the topic to date!
👉Check it out here:
➡️ Check out our latest review 📰 in
@Haematologica
on maintenance therapy 💊 in AML: we discuss what defines a maint Rx, the niche for maint Rx, available data, latest developments and controversies.
@TapKadia
@ Ravandi
Early View | Haematologica
➡️ Check out the commentary to our paper in
@BloodJournal
by
@pvyas_oxford
: Changing treatment changing prognosis of mutations
➡️ Our manuscript is now out in full: Venetoclax & its effects in AML with Splicing factor gene mut
The lifestory of Prof
@DrHKantarjian
: an inspiring showcase of his efforts that has changed the face of leukemia therapy over the last 4 decades. Conferred today the David Karnofsky Award (highest award by
@ASCO
). So fortunate to learn from him and have him leading us 🙏🏼
👉Check out our latest paper
✅In CBF-AML, FLAG based Rx (F-IDA/F-GO) abrogates neg prognostic impact of common kinase mutations
✅PCR<0.01% during/after consolidation➡️superior survival outcomes
✅F-GO leads to better RFS than F-IDA
#leusm
@GBorthakur
Decitabine can prolong/attain molecular remissions and prevent relapse in CBF AML with low level PCR + after complete or attenuated cycles of FLAG based chemo. Data from MDACC
@GBorthakur
Activity of Decitabine as Maintenance Therapy in CBF AML
Medicine:a field where you can never know enough; a lifetime of learning and growing,a palette of evolving science with a subtle touch of art.
14 years from starting MBBS to completion of DM, yet I feel i know so little- I guess thats what defines Science in its truest essence.
Researchers examined the potential independent impact SF gene mutations have on survival outcomes across all patients, both young and old, with
#AML
and across all treatment types, either intensive or low intensity.
@jayastuMD
@MDAndersonNews
🙏🏼 A very appropriate statement we need to remember everyday when we see patients and their caregivers: "Nobody cares how much you know, till they know how much you care."
Any knowledge that is obscured by arrogance or indifference has little benefit in alleviating suffering.
👨🏻⚕️ Finishing touches to the last inpatient rotation as a leukemia fellow. Wonderful one month with
@NitinJainMD
and
@doctorpemm
along with our amazing pharmacists, mid-levels and nurses. All of us working towards one goal ➡️ End Cancer ➡️ End Leukemia 🙏🏼
@MDAndersonNews
👉👉👉Wonderful time finishing up inpatient rounds with our superstar Leukemia fellow MD Dr Jayastu MD .
@jayastuMD
on our last day of the rotation together ➡️ Grateful for Dr Jay’s brilliance, dedication, collegiality, & amazing spirit! 🙏🏾 |
#leusm
#endcancer
👉👉👉 Excited to share results of nivolumab + ibrutinib in patients with Richter Transformation | Published today in
@BloodAdvances
-24 pts DLBCL RT
-Median prior Rx for CLL/RT = 3
-10/24 (42%) had a response (64% BTKi-naive; 23% BTKi-exposed)
-Median DOR 15 mos
#CLL
#lymsm
➡️ Check out our latest paper 📃 TKI in Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL.
Frontline use of BCR::ABL TKIs + chemoimmunotherapy in non-Ph ABL class fusions could lead to improved responses.
@NitinJainMD
@DrHKantarjian
With the curtains coming down on
#ASCO2022
, time for sharing some wonderful memories while gaining momentum for
#EHA2022
. Inspiring mentors and awe inspiring science in the fight to End Cancer!
@MDAndersonNews
#leusm
@ASCO
➡️ Participated as panelist in the Best of ASCO/EHA AML session by
@VJHemOnc
chaired by
@Daver_Leukemia
& moderated by
@jaltmanmd
, C. DiNardo &
@DanPollyea
: discussed our abstract on outcomes of pts >60 yrs old treated on Clad/LDAC/Ven trial led by
@TapKadia
, who had SCT in CR1.
Excited to share our Phase I trial data on the combo of Milademetan, LDAC +/- Ven in R/R TP53 WT AML & ND ts-AML. We performed CyTOF & sc-proteomic analysis to study mechanisms of resistance to therapy.
@ CDiNardo @ Andreeff @ MMuftuoglu
@DrHKantarjian
Maintenance therapy in
#AcuteMyeloidLeukemia
(AML) is a new approach towards preventing relapse. In this review, the authors comprehensively discuss the development of
#AML
#maintenance
therapy over the last 3 decades.
➡️ If you are interested in T-ALL join us in Hall D
#ASH23
@ 5PM today to explore the
@MDAndersonNews
data of HyperCVAD-Nel +/-PegAsp & Ven in F/L Rx of T-ALL
👉🏼 Promising outcomes with progressive improvisation to the Rx
👉🏼 Tolerable regimen
@NitinJainMD
will be at the podium
➡️ Happy to share our latest publication in
@TheLancetHaem
on the outcomes of older pts 👴🏾👵🏻with Ph-B cell ALL treated with MiniHCVD-InO+/-Blina: 5 yr OS of 46% and PFS of 44% ✅ possibly a new benchmark in the Rx of older patients with B-cell ALL
@MDAndersonNews
#leusm
Thanksgiving day leukemia inpatient service with Dr. Sasaki
@MDAndersonNews
skybridge. Wishing everyone a very happy Thanksgiving. Thankful to all those who chose us for their cancer care.
➡️ Check out our poster on display today at
#ASH23
(
#1500
)
👉🏼HR CTG🧬 loses prognostic impact with InO and or Blina added to frontline HyperCVAD chemo in newly diagnosed pts with Ph-ve B-cell ALL
👉🏼 Further analysis underway
@MDAndersonNews
@ Elias Jabbour
The phenomenal "What's new in leukemia in 2021?" talk by Prof. Kantarjian on the backdrop of ASH 2021. Concise, knowledge dense and inspiring.
@MDAndersonNews
@DrHKantarjian
Exciting best of
#ASH23
in Acute Lymphoblastic Leukemia talk today Dr. Elias Jabbour today in the Dept. of Leukemia
@MDAndersonNews
➡️ More effictive InO Blina based regimens in B-ALL
➡️ Ven, Nel, PegAsp in T-ALL
➡️ Fast Off CAR T Obe Cel in B-ALL
...and many others
Some wonderful and engaging moments from San Diego at the US CAR T-cell Rx conference...
honored to hear the evolution and success story of CAR T therapy from the legend himself
@GruppSteve
. Thanks to
@NitinJainMD
@NoopurRajeMD
and @ Sattva Neelapu for the fabulous organisation.
Wonderful start to
#ASCO2022
. Revelling in the science that is to be shared over the next few days and to be in the company of stalwarts who are inching slowly and steadily to End Cancer!
#leusm
Breaks the heart of all those doctors who sacrificed so much to alleviate the suffering of their fellow beings during this COVID-19 pandemic.
@AIIMSRDA
will ensure the Govt takes cognisance of the issue and the strictest punishment is meted out to him.
@MoHFW_INDIA
@PMOIndia
Doctors are ready to sacrifice everything to save INDIA from COVID-19, and such a statement against the saviours is unacceptable.RDA AIIMS request Hon'ble
@AmitShah
Ji to put
@iSunilPal
immediately behind bars under Epidemic Act. He must be punished for it.
#doctorsaresaviours
➡️ Happy to share todays posters
#ASH22
-InO for MRD clearance in B-ALL
@NicholasShortMD
-Dac-Ven-Pon in Ph+myeloid leuk
-Liv elastography for InO liv tox prediction
-Predictors of InO induced VOD
👉🏼 Looking forward to tom's oral on Splice gene mut in AML ✴ Room 353
@4
:45PM
Wonderul CART cell therapy updates by
@NitinJainMD
today. Talk coincides with the
@Nature
paper on long lasting CART cells and decade long CLL remissions at UPenn
🙏🏼 Blessed to be part of this wonderful Leukemia family and be mentored by the giants in the field. A memorable graduation evening as a perfect way to commemorate 2 years of fellowship. Thankful to our Chairman
@DrHKantarjian
and program directors
@garciamanero
and
@TapKadia
Reminiscing a wonderful celebration and year as another fellowship class graduates and moves on to bigger things! Congrats to all the graduates and continuing fellows. It’s been a privilege.
@garciamanero
@DrHKantarjian
💛🎥🎬 There are very few films ever made that captures the symphony and depth of poignant human emotions as the movie MASOOM (1983) does.🌟 An artistic marvel with every watch even 30 yrs later...& the music plays with your soul🎼🎵
@AzmiShabana
, @ Jugal Hansraj
@NaseerudinShah
Captivating Best of
#ASH23
talk by
@NitinJainMD
at Dept of Leukemia
@MDAndersonNews
today
➡️ Time limited therapy is not the best approach for TP53 mut CLL
➡️ Exciting trials ongoing with triplets; ☀️ novel BCL2i
➡️ Ibru+Ven frontline continues to show promising PFS
➡️ Check out our SOHO State of the Art Review on Acute Lymphoblastic Leukemia
✅ Optimizing F/L use of InO and Blina across B-ALL🥇
✅ Pona-Blina chemo free RX in Ph+ B-ALL🏆
✅Reducing NRM in older ALL👴🏽
✅ Nel-PegAsp-Ven in F/L T-ALL💥
✅ Consolidative CART in HR and RR B-ALL💪🏽
@SocietyofHemOnc
State of the art & next questions: ALL
1. F/L InO/Blina +Chemo: deep & durable resp in B-ALL.
2.⬇️chemo is prudent in older pts w/ B-ALL while optimizing InO/Blina use
3. Chemo free Pona+ Blina Rx in Ph+ B-ALL leads to 👍 long-term OS
The Indian "homegrown" vaccine (COVAXIN) works great and the recent approval by W.H.O. is a welcome step.
Efficacy, safety of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
An enchanhting kaleidoscope of diff Indian dance forms performed by
@Samskriti_TX
at
@MillerTheater
Houston today as we reach India's 75th Independence day 🇮🇳. A sense of pride and reflection about our Nation's rich history and vivid cultural heritage!
@DrSJaishankar
@MEAIndia
Honored to meet in person and hear the exhilarating tale of the discovery of CALR mutation in MPN from the prolific
@jyoti_nangalia
at
#ASH22
. Eleven years (2013 ➡️ 2022) of translational research culminating into the first anti CALR mAb ✅ presented at
#ASH22
plenary.
@freezethawed
What you study in the last month matters only around 20%; knowledege accrued bedside over 3 yrs is what takes you through the examination and therafter. Almost everyone who has worked during residency knows enough to pass. So DONT FREAK OUT. Speaking for clinical branches.
Early morning scenes: on the way to attend rounds with Professor
@DrHKantarjian
and leukemia fellow
@FadyyHaddad
.An amazing learning experience it was. Inspired!
➡️ Happy to share todays posters
#ASH22
-InO for MRD clearance in B-ALL
@NicholasShortMD
-Dac-Ven-Pon in Ph+myeloid leuk
-Liv elastography for InO liv tox prediction
-Predictors of InO induced VOD
👉🏼 Looking forward to tom's oral on Splice gene mut in AML ✴ Room 353
@4
:45PM
So happy to have caught up with you at
@ASCO
and inspired by your work and research
@OffCMCVellore
. Sixteen years since the start of our MBBS and to many fond menories! Congratulations on your
@ConquerCancerFd
International Development Award 2023.
@akhilrk1989
@EbyDan2007
Congratulations
@jayastuMD
on your
@ASCO
poster,
@ConquerCancerFd
merit award and
@MDAndersonNews
Leukemia Clinical Fellow of the year! Thanks for showing me around Chicago and for being the amazing person and best friend that you are since 2007
@akhilrk1989
we missed you buddy.
Despite multiple variables, disease status at ASCT remains the strongest prognostic factor in R/R Hodgkin's for post ASCT outcomes. (work done during residency days, published now). Thanks to Prof. Biju George.
@dranupjdevasia
@MathewsVikram
D/W
@VJHemOnc
about our
#EHA2022
abstract on impact of kinase mutations and PCR responses in CBF-AML treated with FLAG (with Gemtuzumab or Idarubicin) regimen. Looking forward to share the full data soon! Mentored by
@GBorthakur
Published by
@VJHemOnc
@jayastuMD
“Bulldozing” through the audience questions after his outstanding presentation on the outcomes of Pts with
#AML
with splicesome mutations at the Oral abstract session
#ASH22
;
@GBorthakur
presiding 😂
🧬 With
#EHA2022
🇦🇹 in full swing and me not able to attend it in person, here is a thread (6) of the abstracts I worked on that will be presented at the conference 📊. Thankful to all my mentors and the Dept of Leukemia
@MDAndersonNews
.
@EHA_Hematology
@DrHKantarjian
#leusm
Wonderful discussion yesterday on advances in MPN by the prolific
@doctorpemm
along with
@mpdrc
(MPN guru Dr Mesa) and Dr. Jamile Shammo. Post session d/w
@doctorpemm
and the team picture👨🏻⚕️
@ASCO
#ASCO2022
Thank you
@doctorpemm
! Looking forward to several such discussions in the future and efforts to turn ideas into reality that should be able to ultimately help our patients and many across the world 👨🏻⚕️👩🏽🔬👨🏼💻
@MDAndersonNews
#leusm
Ending cancer is a global goal; bridging the gap in cancer care is paramount. To everyone
@MDAndersonNews
and the world over in this common fight, every small step in alleviating our patient's suffering is as important as the ultimate magic bullet.
Dedicated to a person who changed the trajectory of Haematology amd stem cell transplantation in India.
Mammen Chandy, MD, FRACP, FRACPA: A Pioneer in India’s Bone Marrow Transplantation Services - The ASCO Post
Very important cost analaysis data for CAR-T cells manufacturing in academic/not-for-profit initiatives. Like India has significantly brought down the cost of SCT while maintaining good outcomes, cellular therapy should be the next focus: cancer care for all, health for all!
Honored to have discussed recent developments in AML and MPN/BPDCN presented at ASH 2021 with
@daver
and
@doctorpemm
on behalf of
@JIPOEditors
.
Small progresses in leukemia sum up to significant improvements in survival!
➡️ Check out our latest review on adv phase CML just published in Curr Hematologic Malignancy Reports 📃
@MDAndersonNews
#leusm
@NicholasShortMD
➡️ Also check out our previous comprehensive review on pathogenesis & Rx of adv phase CML in
@LeukemiaJnl
📰